Conexeu Sciences Inc. Common Stock (CNXU) - Net Assets
Based on the latest financial reports, Conexeu Sciences Inc. Common Stock (CNXU) has net assets worth $7.20 Million USD as of April 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.20 Million) and total liabilities ($1.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Conexeu Sciences Inc. Common Stock annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.20 Million |
| % of Total Assets | 87.76% |
| Annual Growth Rate | 7665.71% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Conexeu Sciences Inc. Common Stock - Net Assets Trend (2024–2025)
This chart illustrates how Conexeu Sciences Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Check how strategically is Conexeu Sciences Inc. Common Stock's equity deployed to assess the company's strategic physical and investment asset allocation.
Annual Net Assets for Conexeu Sciences Inc. Common Stock (2024–2025)
The table below shows the annual net assets of Conexeu Sciences Inc. Common Stock from 2024 to 2025. For live market cap and overall valuation, see Conexeu Sciences Inc. Common Stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-10-31 | $7.35 Million | +7642.61% |
| 2024-10-31 | $94.96K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Conexeu Sciences Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 392355700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (October 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $11.87 Million | 161.49% |
| Total Equity | $7.35 Million | 100.00% |
Conexeu Sciences Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Conexeu Sciences Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BF Utilities Limited
NSE:BFUTILITIE
|
$213.40 Million |
|
AG Mortgage Investment Trust Inc
NYSE:MITT
|
$213.40 Million |
|
Greenpanel Industries Limited
NSE:GREENPANEL
|
$213.47 Million |
|
Orrön Energy AB (publ)
ST:ORRON
|
$213.53 Million |
|
OBOOK Holdings Inc. Class A Common Shares
NASDAQ:OWLS
|
$213.21 Million |
|
Chung Hwa Food Industrial Co Ltd
TWO:4205
|
$213.20 Million |
|
Topco Technologies
TWO:3388
|
$213.04 Million |
|
Evgo Inc
NASDAQ:EVGO
|
$213.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Conexeu Sciences Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 94,964 to 7,352,693, a change of 7,257,729 (7642.6%).
- Net loss of 3,923,557 reduced equity.
- New share issuances of 6,423,957 increased equity.
- Other factors increased equity by 4,757,329.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.92 Million | -53.36% |
| Share Issuances | $6.42 Million | +87.37% |
| Other Changes | $4.76 Million | +64.7% |
| Total Change | $- | 7642.61% |
Book Value vs Market Value Analysis
This analysis compares Conexeu Sciences Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 25.29x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 1958.06x to 25.29x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-10-31 | $0.00 | $8.89 | x |
| 2025-10-31 | $0.35 | $8.89 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Conexeu Sciences Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -53.36%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.05x
- Recent ROE (-53.36%) is above the historical average (-275.13%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | -496.89% | 0.00% | 0.00x | 5.62x | $-481.36K |
| 2025 | -53.36% | 0.00% | 0.00x | 1.05x | $-4.66 Million |
Industry Comparison
This section compares Conexeu Sciences Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $222,336,533
- Average return on equity (ROE) among peers: -76.88%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Conexeu Sciences Inc. Common Stock (CNXU) | $7.20 Million | -496.89% | 0.14x | $213.26 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $148.49 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.82 Million | -556.02% | 2.44x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.59 Billion |
| Arbutus Biopharma Corp (ABUS) | $76.58 Million | -43.75% | 0.24x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $23.14 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $10.02 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $479.08 Million | -51.18% | 0.13x | $5.07 Billion |
About Conexeu Sciences Inc. Common Stock
Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, b… Read more